Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

NCT04807673 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

342

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel
DRUG: Cisplatin
RADIATION: neoadjuvant chemoradiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]